PSMA PET/CT is increasingly used as a metastatic screening tool in patients with a primary diagnosis of PCa [7] and may indeed be of value for the assessment of the local extent of the primary prostate tumour as well. Here, FOLH1 is linked to posterior cortical atrophy.